{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:26Z","timestamp":1789794146134,"version":"4.0.1"},"reference-count":58,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/bst.2026.01219","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:11:11Z","timestamp":1787868671000},"page":"361-372","source":"Crossref","is-referenced-by-count":0,"title":["Management of dynamic therapeutic opportunity in hepatocellular carcinoma: Preserving liver function and enabling treatment transitions"],"prefix":"10.5582","volume":"20","author":[{"given":"Jiwei","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingheng","family":"Liao","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan."},{"name":"Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315-374."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Singal AG, Llovet JM, Yarchoan M, <i>et al.<\/i> AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922-1965.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vogel A, Martinelli E; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma from the ESMO Clinical Practice Guideline. Ann Oncol. 2021; 32:801-805.","DOI":"10.1016\/j.annonc.2021.02.014"},{"key":"4","unstructured":"4. Department of Medical Administration, National Health Commission of the People\u2032s Republic of China. Guideline for diagnosis and treatment of primary liver cancer (2026 edition). Chinese Journal of Digestive Surgery, 2026; 25:423-482. (in Chinese)"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. Semin Surg Oncol. 1993; 9:298-304.","DOI":"10.1002\/ssu.2980090404"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: Decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005; 12:16-22.","DOI":"10.1007\/s00534-004-0965-9"},{"key":"7","unstructured":"7. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report. Surgery. 1990; 107:521-527."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005; 242:252-259.","DOI":"10.1097\/01.sla.0000171307.37401.db"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Aramaki O, Takayama T, Matsuyama Y, <i>et al.<\/i> Reevaluation of Makuuchi&apos;s criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey. Hepatol Res. 2023; 53:127-134.","DOI":"10.1111\/hepr.13844"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Reig M, Sanduzzi-Zamparelli M, Forner A, <i>et al.<\/i> BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026; 84:631-654.","DOI":"10.1016\/j.jhep.2025.10.020"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, Ricke J, Rimassa L, Sapisochin G, Vilgrain V, Zucman-Rossi J, Ducreux M. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025; 36:491-506.","DOI":"10.1016\/j.annonc.2025.02.006"},{"key":"12","unstructured":"12. Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma 2025. Japan Society of Hepatology, Tokyo, Japan, 2025. Japanese."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Johnson PJ, Berhane S, Kagebayashi C, <i>et al.<\/i> Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach\u2014the ALBI grade. J Clin Oncol. 2015; 33:550-558.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, <i>et al.<\/i> \u03b2-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019; 9:1124-1141.","DOI":"10.1158\/2159-8290.CD-19-0074"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Harding JJ, Nandakumar S, Armenia J, <i>et al.<\/i> Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019; 25:2116-2126.","DOI":"10.1158\/1078-0432.CCR-18-2293"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res. 2021; 9:91.","DOI":"10.1186\/s40364-021-00348-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, Wang F, Zhang L, Deng Y. Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. Front Nutr. 2022; 9:978110.","DOI":"10.3389\/fnut.2022.978110"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kuo MH, Tseng CW, Hsu CS, Chen YC, Kao IT, Wu CY, Shao SC. Prevalence and effect of low skeletal muscle mass among hepatocellular carcinoma patients undergoing systemic therapy: A systematic review and meta-analysis. Cancers (Basel). 2023; 15:2426.","DOI":"10.3390\/cancers15092426"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Finn RS, Qin S, Ikeda M, <i>et al.<\/i> Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cheng AL, Qin S, Ikeda M, <i>et al.<\/i> Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76:862-873.","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Abou-Alfa GK, Lau G, Kudo M, <i>et al.<\/i> Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022; 1:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sangro B, Kudo M, Qin S, <i>et al.<\/i> Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024; 35:448-457.","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Qin S, Chan SL, Gu S, <i>et al.<\/i> Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study. Lancet. 2023; 402:1133-1146.","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yau T, Galle PR, Decaens T, <i>et al.<\/i> Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW). Lancet. 2025; 405:1851-1864.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bruix J, Qin S, Merle P, <i>et al.<\/i> Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE). Lancet. 2017; 389:56-66.","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Abou-Alfa GK, Meyer T, Cheng AL, <i>et al.<\/i> Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018; 379:54-63.","DOI":"10.1056\/NEJMoa1717002"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zhu AX, Kang YK, Yen CJ, <i>et al.<\/i> Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2). Lancet Oncol. 2019; 20:282-296.","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Melero I, Yau T, Kang YK, <i>et al.<\/i> Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Ann Oncol. 2024; 35:537-548.","DOI":"10.1016\/j.annonc.2024.03.005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kudo M, Han G, Finn RS, <i>et al.<\/i> Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology. 2014; 60:1697-1707.","DOI":"10.1002\/hep.27290"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kudo M, Han KH, Ye SL, <i>et al.<\/i> A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert consensus statements. Liver Cancer. 2020; 9:245-260.","DOI":"10.1159\/000507370"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kudo M, Ueshima K, Chan S, <i>et al.<\/i> Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. Cancers (Basel). 2019; 11:1084.","DOI":"10.3390\/cancers11081084"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan. Oncology. 2014; 87 Suppl 1:32-36.","DOI":"10.1159\/000368143"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kodama Y, Ikeda M, Arai Y, <i>et al.<\/i> Change in liver function after selective transarterial chemoembolization for unresectable hepatocellular carcinoma: JIVROSG-2001 PRESIDENT-ALBI, a secondary analysis of a multicenter randomized controlled trial. Liver Cancer. Published online December 5, 2025.","DOI":"10.1159\/000549879"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sangro B, Kudo M, Erinjeri JP, <i>et al.<\/i> Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1). Lancet. 2025; 405:216-232.","DOI":"10.1016\/S0140-6736(24)02551-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kudo M, Ren Z, Guo Y, <i>et al.<\/i> Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012). Lancet. 2025; 405:203-215.","DOI":"10.1016\/S0140-6736(24)02575-3"},{"key":"36","unstructured":"36. Merck &amp; Co., Inc.; Eisai Co., Ltd. Merck and Eisai provide update on phase 3 LEAP-012 trial in unresectable, non-metastatic hepatocellular carcinoma. <i>https:\/\/www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-leap-012-trial-in-unresectable-non-metastatic-hepatocellular-carcinoma\/<\/i> (accessed August 15, 2026)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Abou-Alfa GK, Ren Z, Erinjeri JP, <i>et al.<\/i> Efficacy and safety results from EMERALD-3: tremelimumab plus durvalumab with or without lenvatinib combined with TACE in embolization-eligible HCC. J Clin Oncol. 2026; 44(suppl 17):LBA4000.","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4000"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022; 40:468-480.","DOI":"10.1200\/JCO.21.01963"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. He M, Li Q, Zou R, <i>et al.<\/i> Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial. JAMA Oncol. 2019; 5:953-960.","DOI":"10.1001\/jamaoncol.2019.0250"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Salem R, Gordon AC, Mouli S, <i>et al.<\/i> Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016; 151:1155-1163.e2.","DOI":"10.1053\/j.gastro.2016.08.029"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. Y-90 radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: Results from the TRACE phase II randomized controlled trial. Radiology. 2022; 303:699-710.","DOI":"10.1148\/radiol.211806"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Dawson LA, Winter KA, Knox JJ, <i>et al.<\/i> Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025; 11:136-144.","DOI":"10.1001\/jamaoncol.2024.5403"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Qin S, Chen M, Cheng AL, <i>et al.<\/i> Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050). Lancet. 2023; 402:1835-1847.","DOI":"10.1016\/S0140-6736(23)01796-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PKH. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026; 84:1102-1111.","DOI":"10.1016\/j.jhep.2026.01.006"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Wang Z, Fan J, Zhou S, <i>et al.<\/i> Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): A randomized phase 2\/3 trial. Lancet. 2025; 406:2089-2099.","DOI":"10.1016\/S0140-6736(25)01720-9"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sun HC, Shen F, Liu L, <i>et al.<\/i> Liver resection versus continued atezolizumab plus bevacizumab in locally advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment (TALENTop): A multicentre, open-label, randomised phase 3 trial. Ann Oncol. 2025; 36(suppl):abstract 1469MO.","DOI":"10.1016\/j.annonc.2025.08.2099"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Okuno M, Ishii T, Ichida A, Soyama A, Takemura N, Hirono S, Eguchi S, Hasegawa K, Sasaki Y, Uemura K, Kokudo N, Hatano E. Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab. BMC Cancer. 2023; 23:780.","DOI":"10.1186\/s12885-023-11302-6"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Shimose S, Saeki I, Ito T, <i>et al.<\/i> The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using oncological resectability criteria in Japan. Hepatol Int. 2025; 19:846-855.","DOI":"10.1007\/s12072-025-10781-y"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Takeuchi Y, Sue M, Miyake N, <i>et al.<\/i> Borderline resectable classification identifies candidates for conversion therapy in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Hepatol Res. 2026; 56:830-839.","DOI":"10.1111\/hepr.70138"},{"key":"50","unstructured":"50. National Library of Medicine. DailyMed: Avastin (bevacizumab) injection, solution. <i>https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e<\/i> (accessed August 15, 2026)."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Schnickel GT, Fabbri K, Hosseini M, Misel M, Berumen J, Parekh J, Mekeel K, Dehghan Y, Kono Y, Ajmera V. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant. 2022; 22:1699-1704.","DOI":"10.1111\/ajt.16965"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Rezaee-Zavareh MS, Yeo YH, Wang T, <i>et al.<\/i> Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025; 82:107-119.","DOI":"10.1016\/j.jhep.2024.09.019"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease: executive summary. Diabetologia. 2024; 67:2375-2392.","DOI":"10.1007\/s00125-024-06196-3"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77:1797-1835.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. El Dahan KS, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, Zhu H, Patel MS, del Pilar Bayona Molano M, Sanford N, Gopal P, Parikh ND, Yopp AC, Singal AG. Multidisciplinary care for patients with HCC: A systematic review and meta-analysis. Hepatol Commun. 2023; 7:e0143.","DOI":"10.1097\/HC9.0000000000000143"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Cabibbo G, Celsa C, Bhoori S, Reiberger T, Pinato DJ, Camm\u00e0 C. Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma. J Hepatol. 2025; 83:1443-1451.","DOI":"10.1016\/j.jhep.2025.07.020"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012; 33:176-182.","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Uno H, Claggett B, Tian L, <i>et al.<\/i> Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014; 32:2380-2385.","DOI":"10.1200\/JCO.2014.55.2208"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01219\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:29:44Z","timestamp":1789792184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01219\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01219","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01219"}}